Inozyme Pharma, Inc. Common Stock(INZY)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $3.97 – $4.00
- IV Rank (30D)
- 72.0
- Straddle Price
- $0.00
- P/C Vol Ratio
- 0.19
- Market Cap
- $0.3B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.3B
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +14.67% | 5 |
| Feb | +1.33% | 5 |
| Mar | +12.79% | 5 |
| Apr | -5.81% | 5 |
| May | +54.62% | 5 |
| Jun | +2.95% | 5 |
| Jul | +0.18% | 4 |
| Aug | -4.59% | 4 |
| Sep | -15.11% | 4 |
| Oct | -14.12% | 4 |
| Nov | -10.65% | 4 |
| Dec | -4.61% | 4 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-06 | After-Close | 18.88% | 9.59% | 0.51x | Within |
| 2024-11-05 | After-Close | 30.70% | 6.02% | 0.20x | Within |
| 2025-01-10 | After-Close | 48.08% | 14.35% | 0.30x | Within |
| 2025-03-10 | After-Close | 78.83% | 2.71% | 0.03x | Within |
- IV Rank (30D)
- 72.0
- IV Rank (7D)
- 72.0
- Avg IV
- 760.0%
- Straddle (30D)
- $0.00
- Straddle (7D)
- $0.00
- P/C Volume
- 0.19
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2025-06-27 | Matthew Winton | COO | Award (A) | +14,355 | $0.74 | $10.6K | EDGAR |
| 2025-06-27 | Douglas A Treco | CEO & Chairman | Award (A) | +2,815 | $0.74 | $2.1K | EDGAR |
| 2025-06-27 | Sanjay Subramanian | SVP, CFO & Head of BD | Award (A) | +6,813 | $0.74 | $5.0K | EDGAR |
| 2025-05-20 | Axel Bolte | Director | Exer (M) | +157,230 | $0.98 | $154.1K | EDGAR |
| 2025-04-03 | Douglas A Treco | CEO & Chairman | Mixed | +16,181 | $0.89 | -$7.8K | EDGAR |
| 2025-04-02 | Matthew Winton | COO | Award (A) | +2,490 | $0.77 | $1.9K | EDGAR |
| 2025-04-02 | Sanjay Subramanian | SVP, CFO & Head of BD | Award (A) | +2,490 | $0.77 | $1.9K | EDGAR |
| 2025-03-17 | Matthew Winton | COO | Grant (A) | +186,500 opt | — | EDGAR | |
| 2025-03-17 | Sanjay Subramanian | SVP, CFO | Grant (A) | +183,500 opt | — | EDGAR | |
| 2025-03-17 | Douglas A Treco | CEO | Grant (A) | +500,000 RSU | — | EDGAR | |
| 2024-10-07 | Erik Harris | Director | Grant (A) | +56,000 opt | — | EDGAR | |
| 2024-10-03 | Matthew Winton | COO | Award (A) | +1,710 | $4.45 | $7.6K | EDGAR |
| 2024-10-03 | Douglas A Treco | CEO | Award (A) | +1,710 | $4.45 | $7.6K | EDGAR |
| 2024-06-20 | Robert Lorne Hopfner | Director | Grant (A) | +28,000 opt | — | EDGAR | |
| 2024-06-20 | Martin Edwards | Director | Grant (A) | +28,000 opt | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Longitude Venture Partners III, L.P. | 10%+ Owner | 4,174,379 | $16.70M | $20.00M | 1 | 2022-04-21 |
| 2 | Robert Lorne Hopfner | Director | 2,923,110 | $11.69M | $16.20M | 11 | 2024-06-20 |
| 3 | NEA 15 GP, LLC | 10%+ Owner | 2,437,689 | $9.75M | $12.00M | 1 | 2020-07-28 |
| 4 | Mohamad Makhzoumi | 10%+ Owner | 2,437,689 | $9.75M | $4.00M | 1 | 2020-07-28 |
| 5 | Novo Holdings A/S | 10%+ Owner | 2,194,379 | $8.78M | -$1.88M | 2 | 2021-02-01 |
| 6 | SCOTT D SANDELL | 10%+ Owner | 2,187,689 | $8.75M | $4.00M | 1 | 2020-07-28 |
| 7 | Peter W. Sonsini | 10%+ Owner | 2,187,689 | $8.75M | $4.00M | 1 | 2020-07-28 |
| 8 | PATRICK G ENRIGHT | 10%+ Owner | 2,007,225 | $8.03M | $40.00M | 1 | 2020-07-28 |
| 9 | JOSHUA MAKOWER | 10%+ Owner | 2,000,533 | $8.00M | $4.00M | 1 | 2020-07-28 |
| 10 | FOREST BASKETT | 10%+ Owner | 2,000,533 | $8.00M | $4.00M | 1 | 2020-07-28 |
| 11 | Anthony A. Jr. Florence | 10%+ Owner | 2,000,533 | $8.00M | $4.00M | 1 | 2020-07-28 |
| 12 | Maha Katabi | 10%+ Owner | 1,590,808 | $6.36M | $35.00M | 1 | 2020-07-28 |
| 13 | Pivotal bioVenture Partners Fund I U.G.P. Ltd | Director | 1,571,741 | $6.29M | $32.84M | 3 | 2023-08-03 |
| 14 | Rajeev M. Shah | 10%+ Owner | 1,403,653 | $5.61M | $28.80M | 1 | 2020-07-28 |
| 15 | ALEXION PHARMACEUTICALS, INC. | 10%+ Owner | 1,109,910 | $4.44M | $0 | 1 | 2020-07-28 |
| 16 | Rock Springs Capital LLC | 10%+ Owner | 467,884 | $1.87M | $28.80M | 1 | 2020-07-28 |
| 17 | Sanofi | 10%+ Owner | 438,875 | $1.76M | $1.30M | 1 | 2020-07-29 |
| 18 | Axel Bolte | Director | 423,926 | $1.70M | $250.0K | 12 | 2025-05-20 |
| 19 | Joseph Schlessinger | 10%+ Owner | 286,479 | $1.15M | $0 | 1 | 2020-07-28 |
| 20 | Henric Bjorn Bjarke | SVP, COO | 105,441 | $421.8K | $129.9K | 7 | 2022-12-19 |
| 21 | Steven J Jungles | SVP, CTO | 55,417 | $221.7K | $0 | 3 | 2021-03-17 |
| 22 | Douglas A Treco | CEO & Chairman | 43,861 | $175.4K | -$60.1K | 10 | 2025-06-27 |
| 23 | Sanjay Subramanian | SVP, CFO & Head of BD | 39,701 | $158.8K | $100.0K | 9 | 2025-06-27 |
| 24 | Matthew Winton | COO | 21,743 | $87.0K | $0 | 7 | 2025-06-27 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.